Search
01/06/2022
SELNET clinical practice guidelines for bone sarcoma
Blay, JY, Palmerini, E, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sanchez, CHS, Montoya, AC, Casavilca-Zambrano, S, Castro-Oliden, V, Chacon, M, Clara-Altamirano, MA, Collini, P, Genoroso, RC, Costa, FD, Cuellar, M, Tos, APD, Malagon, HRD, Donati, DM, Dufresne, A, Eriksson, M, Farias-Loza, M, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gerderblom, H, Gouin, F, Gomez-Mateo, MC, Gronchi, A, Haro, J, Hindi, N, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, Lopes, A, David, BBL, Lopez-Pousa, A, Lutter, G, Maki, RG, Martinez-Said, H, Martinez-Tlahuel, JL, Mello, CA, Perez, JMM, Moura, DS, Nakagawa, SA, Nascimento, AG, Ortiz-Cruz, EJ, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Santos, TG, Scotlandi, K, Silva, MLG, Soule, T, Stacchiotti, S, Valverde, CM, Waisberg, F, Estrada, EZ, Martin-Broto, J. SELNET clinical practice guidelines for bone sarcoma. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174DOI:10.1016/j.critrevonc.2022.103685. PMID:35460913. IF:6.200(Q1/3D).
01/06/2022
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
Lindskog, M, Laurell, A, Kjellman, A, Melichar, B, Rey, PM, Zielinski, H, Villacampa, F, Bigot, P, Zoltan, B, Parikh, O, Alba, DV, Jellvert, D, Flasko, T, Gallardo, E, Caparros, MJR, Purkalne, G, Suenaert, P, Karlsson-Parra, A, Ljungberg, B. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science. 2022; 40DOI:10.1016/j.euros.2022.03.012. PMID:35638086. IF:2.500(Q3/6D).
01/06/2022
The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles
Volta-Duran, E, Sanchez, JM, Hector-Lopez-Laguna, Parlade, E, Sanchez-Garcia, L, Sanchez-Chardi, A, de Marco, A, Unzueta, U, Vazquez, E, Villaverde, A. The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles. Science China-Materials. 2022; 65(6)DOI:10.1007/s40843-021-1914-0. PMID:. IF:8.100(Q1/3D).
01/06/2022
Sarcoidosis following SARS-CoV-2 infection: Cause or consequence?
Palones, E, Pajares, V, Lopez, L, Castillo, D, Torrego, A. Sarcoidosis following SARS-CoV-2 infection: Cause or consequence?. Respirology Case Reports. 2022; 10(6)DOI:10.1002/rcr2.955. PMID:35505665. IF:(Q/D).
01/06/2022
The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours
Lopez, F, Shah, JP, Beitler, JJ, Snyderman, CH, Lund, V, Piazza, C, Makitie, AA, Guntinas-Lichius, O, Rodrigo, JP, Kowalski, LP, Quer, M, Shaha, A, Homma, A, Sanabria, A, Ferrarotto, R, Lee, AWM, Lee, VHF, Rinaldo, A, Ferlito, A. The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours. ADVANCES IN THERAPY. 2022; 39(6)DOI:10.1007/s12325-022-02080-x. PMID:35352310. IF:3.800(Q2/4D).
01/06/2022
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper
Zozaya, N, Villaseca, J, Abdalla, F, Calleja, MA, Diez-Martin, JL, Estevez, J, Garcia-Sanz, R, Martinez-Lopez, J, Sierra, J, Vera, R, Hidalgo-Vega, A. A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. Clinical & Translational Oncology. 2022; 24(6)DOI:10.1007/s12094-021-02757-9. PMID:34997475. IF:3.400(Q3/6D).
01/06/2022
Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk
Lopez, S, Martinez-Perez, A, Rodriguez-Rius, A, Vinuela, A, Brown, AA, Martin-Fernandez, L, Vilalta, N, Arus, M, Panousis, NI, Buil, A, Sabater-Lleal, M, Souto, JC, Dermitzakis, ET, Soria, JM. Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk. THROMBOSIS AND HAEMOSTASIS. 2022; 122(06)DOI:10.1055/s-0041-1742169. PMID:35272364. IF:6.700(Q1/2D).
01/06/2022
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
Bazarbachi, A, Boumendil, A, Finel, H, Khvedelidze, I, Romejko-Jarosinska, J, Tanase, A, Akhtar, S, Ben Othman, T, Ma'koseh, M, Afanasyev, B, Cheikh, J, Briones, J, Gulbas, Z, Hamladji, RM, Elverdi, T, Blaise, D, Martinez, C, Alma, E, Halaburda, K, Sousa, AB, Glass, B, Robinson, S, Montoto, S, Sureda, A. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. LEUKEMIA. 2022; 36(6)DOI:10.1038/s41375-022-01563-8. PMID:35414657. IF:11.400(Q1/1D).